Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity

European Journal of Immunology

Volumn 43, Issue 9, 2013, Pages 2484-2496

  Miah, Mohammad Alam ^a,b   Byeon, Se Eun ^a   Ahmed, Md Selim ^a   Yoon, Cheol Hee ^a   Ha, Sang Jun ^c   Bae, Yong Soo ^a,d  

^a Sungkyunkwan University   (South Korea)

^b BANGLADESH AGRICULTURAL UNIVERSITY   (Bangladesh)

^c Yonsei University   (South Korea)

^d CreaGene Research Institute   (South Korea)

Author keywords

DC development; Egr2; Immunotherapy; Negative regulator; Th1 immunity

Indexed keywords

DENDRITIC CELL VACCINE; EARLY GROWTH RESPONSE FACTOR 2; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CELL LEVEL; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DEVELOPMENTAL STAGE; FEMALE; GENE SILENCING; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; IMMUNOGENICITY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATOR GENE; SPLEEN CELL; STEADY STATE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY;

DC DEVELOPMENT; EGR2; IMMUNOTHERAPY; NEGATIVE REGULATOR; TH1 IMMUNITY;

ANIMALS; BONE MARROW CELLS; CANCER VACCINES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; EARLY GROWTH RESPONSE PROTEIN 2; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPLEEN; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84883499436     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201243046     Document Type: Article

References (36)

1. Onai, N. and Manz, M. G., The STATs on dendritic cell development. Immunity 2008. 28: 490-492.
2. Miah, M. A., Yoon, C. H., Kim, J., Jang, J., Seong, Y. R. and Bae, Y. S., CISH is induced during DC development and regulates DC-mediated CTL activation. Eur. J. Immunol. 2012. 42: 58-68.
3. Lauritsen, J. P., Kurella, S., Lee, S. Y., Lefebvre, J. M., Rhodes, M., Alberola-Ila, J. and Wiest, D. L., Egr2 is required for Bcl-2 induction during positive selection. J. Immunol. 2008. 181: 7778-7785.
4. Lawson, V. J., Weston, K. and Maurice, D., Early growth response 2 regulates the survival of thymocytes during positive selection. Eur. J. Immunol. 2010. 40: 232-241.
5. Harris, J. E., Bishop, K. D., Phillips, N. E., Mordes, J. P., Greiner, D. L., Rossini, A. A. and Czech, M. P., Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J. Immunol. 2004. 173: 7331-7338.
6. Zhu, B., Symonds, A. L., Martin, J. E., Kioussis, D., Wraith, D. C., Li, S. and Wang, P., Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupus like autoimmune disease. J. Exp. Med. 2008. 205: 2295-2307.
7. Myouzen, K., Kochi, Y., Shimane, K., Fujio, K., Okamura, T., Okada, Y., Suzuki, A. et al., Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus. Hum. Mol. Genet. 2010. 19: 2313-2320.
8. Okamura, T., Fujio, K., Shibuya, M., Sumitomo, S., Shoda, H., Sakaguchi, S. and Yamamoto, K., CD4+CD25-LAG3 +regulatory T cells controlled by the transcription factor Egr-2. Proc. Natl. Acad. Sci. USA 2009. 106: 13974-13979.
9. Ramon, H. E., Cejas, P. J., LaRosa, D., Rahman, A., Harris, J. E., Zhang, J., Hunter, C. et al., EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PLoS ONE 2010. 5: e12904.
10. Carter, J. H. and Tourtellotte, W. G., Early growth response transcriptional regulators are dispensable for macrophage differentiation. J. Immunol. 2007. 178: 3038-3047.
11. Arthur-Farraj, P., Mirsky, R., Parkinson, D. B. and Jessen, K. R., A double point mutation in the DNA-binding region of Egr2 switches its function from inhibition to induction of proliferation: a potential contribution to the development of congenital hypomyelinating neuropathy. Neurobiol. Dis. 2006. 24: 159-169.
12. Bradley, E. W., Ruan, M. M. and Oursler, M. J., Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway. J. Biol. Chem. 2008. 283: 8055-8064.
13. Unoki, M. and Nakamura, Y., EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene 2003. 22: 2172-2185.
14. Yokota, I., Sasaki, Y., Kashima, L., Idogawa, M. and Tokino, T., Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene. Int. J. Oncol. 2010. 37: 1407-1416.
15. Lazarevic, V., Zullo, A. J., Schweitzer, M. N., Staton, T. L., Gallo, E. M., Crabtree, G. R. and Glimcher, L. H., The gene encoding early growth response 2, a target of the transcription factor NFAT, is required for the development and maturation of natural killer T cells. Nat. Immunol. 2009. 10: 306-313.
16. Lejard, V., Blais, F., Guerquin, M. J., Bonnet, A., Bonnin, M. A., Havis, E., Malbouyres, M. et al., EGR1 and EGR2 involvement in vertebrate tendon differentiation. J. Biol. Chem. 2010. 286: 5855-5867.
17. Chen, Z., Torrens, J. I., Anand, A., Spiegelman, B. M. and Friedman, J. M., Krox20 stimulates adipogenesis via C/EBPbeta-dependent and -independent mechanisms. Cell. Metab. 2005. 1: 93-106.
18. Goodridge, H. S., Simmons, R. M. and Underhill, D. M., Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J. Immunol. 2007. 178: 3107-3115.
19. Platt, C. D., Ma, J. K., Chalouni, C., Ebersold, M., Bou-Reslan, H., Carano, R. A., Mellman, I. et al., Mature dendritic cells use endocytic receptors to capture and present antigens. Proc. Natl. Acad. Sci. USA 2010. 107: 4287-4292.
20. Evel-Kabler, K., Song, X. T., Aldrich, M., Huang, X. F. and Chen, S. Y., SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 2006. 116: 90-100.
21. Gashler, A. and Sukhatme, V. P., Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog. Nucleic Acid Res. Mol. Biol. 1995. 50: 191-224.
22. Mages, H. W., Stamminger, T., Rilke, O., Bravo, R. and Kroczek, R. A., Expression of PILOT, a putative transcription factor, requires two signals and is cyclosporin A sensitive in T cells. Int. Immunol. 1993. 5: 63-70.
23. Milbrandt, J., A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 1987. 238: 797-799.
24. Christy, B. A., Lau, L. F. and Nathans, D., A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. Proc. Natl. Acad. Sci. USA 1988. 85: 7857-7861.
25. Lemaire, P., Revelant, O., Bravo, R. and Charnay, P., Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. Proc. Natl. Acad. Sci. USA 1988. 85: 4691-4695.
26. Zheng, Y., Zha, Y., Driessens, G., Locke, F. and Gajewski, T. F., Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J. Exp. Med. 2012. 209: 2157-2163.
27. Shen, L., Evel-Kabler, K., Strube, R. and Chen, S. Y., Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 2004. 22: 1546-1553.
28. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27.
29. Lim, D. S., Kim, J. H., Lee, D. S., Yoon, C. H. and Bae, Y. S., DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol. Immunother. 2007. 56: 1817-1829.
30. Haeryfar, S. M., Conrad, D. M., Musgrave, B. and Hoskin, D. W., Antibody blockade of Thy-1 (CD90) impairs mouse cytotoxic T lymphocyte induction by anti-CD3 monoclonal antibody. Immunol. Cell Biol. 2005. 83: 352-363.
31. Ha, J. E., Choi, Y. E., Jang, J., Yoon, C. H., Kim, H. Y. and Bae, Y. S., FLIP and MAPK play crucial roles in the MLN51-mediated hyperproliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. FEBS J. 2008. 275: 3546-3555.
32. Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H. I., Antonia, S., Altiok, S. et al., Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010. 120: 1111-1124.
33. Russell, J. H. and Ley, T. J., Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 2002. 20: 323-370.
34. Jensen, M. M., Jorgensen, J. T., Binderup, T. and Kjaer, A., Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med. Imaging 2008. 8: 16.
35. Sun, K., Li, M., Sayers, T. J., Welniak, L. A. and Murphy, W. J., Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 2008. 112: 1522-1529.
36. Liu, C., Wang, Q., Liu, F., Li, H., Zhu, F., Wang, X., Guo, C. et al., The allogeneic but not syngeneic dendritic cells effectively generated regulatory T cells from total CD4+ population without exogenous cytokines. Scand. J. Immunol. 2010. 71: 12-19.